Cassava Sciences | PTIE - Operating Expenses


Cassava Sciences reported $11.86M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Abbott USD 9.21B 17M Dec/2025
Amgen USD 5.9B 773M Dec/2025
Biogen USD 1.88B 81.4M Sep/2025
Cara Therapeutics USD 4.96M 2.38M Mar/2025
Cassava Sciences USD 11.86M 2.23M Sep/2025
Eisai JPY 199.9B 16.22B Dec/2025
Eli Lilly USD 10.31B 1.09B Dec/2025
Geron USD 61.11M 376K Sep/2025
J&J USD 18.97B 2.38B Dec/2025
Merck USD 10.16B 558M Dec/2025
Novartis USD 9.86B 115M Sep/2025
Novavax USD 218.53M 34.86M Sep/2024
Pfizer USD 12.91B 79.89B Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025